SpecificityBy immunoblotting, the antibody shows less than 1% cross-reactivity with recombinant human GRO-beta under reducing conditions and less than 1% cross-reactivity with recombinant mouse JE under non-reducing conditions.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration. The ND50 for this effect is approximately 0.08-0.4µg/ml in the presence of 0.02µg/ml of recombinant human IL8 using hCXCR-2 transfected BaF/3 cells.
Use a concentration of 4 µg/ml.
Use a concentration of 25 µg/ml. For flow cytometry (intracellular staining), the cells must first be fixed and permeabilized using 4% paraformaldehyde and 0.1% saponin.
ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 11 kDa. The detection limit for in WB for recombinant human IL8 is approximately 0.5 ng/lane under non-reducing and reducing conditions in SDS PAGE.
FunctionIL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.
Sequence similaritiesBelongs to the intercrine alpha (chemokine CxC) family.
Post-translational modificationsSeveral N-terminal processed forms are produced by proteolytic cleavage after secretion from at least peripheral blood monocytes, leukcocytes and endothelial cells. In general, IL-8(1-77) is referred to as interleukin-8. IL-8(6-77) is the most promiment form.